MaxCyte Analyst Price Targets - Benzinga

MaxCyte Inc

MXCTNASDAQ

Trade with Public

Trade with Public

$1.43

0.1310%

最終更新: Oct 20, 4:31 PM

$1.40

0.17.69%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

MaxCyte Analyst Price Targets - Benzinga

MaxCyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for MaxCyte (MXCT).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

3Buy

2Hold

Consensus RatingOverweight# Analysts5Avg. Consensus PT$8Upside to Avg. PT+453.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 25, 2026	Craig-Hallum	Matt Hewitt	PT Cut	Buy	$7→$5
Aug 11, 2025	BTIG	Mark Massaro	Downgrade	Buy→Neutral	—
Aug 7, 2025	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
Jul 22, 2025	Stephens & Co.	Helfey Hannah	Assumes	Overweight	$6
Mar 12, 2025	Stifel	Daniel Arias	PT Cut	Buy	$11→$9
Apr 23, 2024	Stephens & Co.	Jacob Johnson	Maintained	Overweight	$11
Mar 13, 2024	Stephens & Co.	Jacob Johnson	Maintained	Overweight	$11
Mar 13, 2024	BTIG	Mark Massaro	PT Cut	Buy	$10→$8
Nov 29, 2023	Craig-Hallum	Matt Hewitt	Initiate	Buy	$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $7 to $5.

Benzinga Newsdesk

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Avi Kapoor

PRO
BTIG Downgrades MaxCyte to Neutral

BTIG analyst Mark Massaro downgrades MaxCyte (NASDAQ:MXCT) from Buy to Neutral.

Benzinga Newsdesk

PRO
William Blair Downgrades MaxCyte to Market Perform

William Blair analyst Matt Larew downgrades MaxCyte (NASDAQ:MXCT) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Stephens & Co. Assumes MaxCyte at Overweight, Announces Price Target of $6

Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on MaxCyte, Lowers Price Target to $9

Stifel analyst Daniel Arias maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $11 to $9.

Benzinga Newsdesk